SUFENTANIL CITRATE INJECTION 50 MCG
SUFENTANIL (SUFENTANIL CITRATE) : 50 MCG · DIN 02483181 · HIKMA CANADA LIMITED
Health Canada status: APPROVED
What is SUFENTANIL CITRATE INJECTION?
SUFENTANIL CITRATE INJECTION 50 MCG contains SUFENTANIL (SUFENTANIL CITRATE) : 50 MCG. It is listed in the Health Canada Drug Product Database under DIN 02483181, held by HIKMA CANADA LIMITED, supplied as SOLUTION for EPIDURAL ; INTRAVENOUS administration. Health Canada currently lists it as approved, status dated 07-Jun-2022. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
Product details and regulatory record
| DIN | 02483181 |
|---|---|
| Brand name | SUFENTANIL CITRATE INJECTION |
| Generic / active ingredient | SUFENTANIL (SUFENTANIL CITRATE) : 50 MCG |
| Manufacturer | HIKMA CANADA LIMITED |
| Strength | 50 MCG |
| Dosage form | SOLUTION |
| Route of administration | EPIDURAL ; INTRAVENOUS |
| Schedule | NARCOTICS (CDSA I) |
| ATC code | N01AH03 SUFENTANIL |
| AHFS class | 28:08.08 |
| Biosimilar | No |
| Health Canada status | APPROVED |
| Status date | 07-Jun-2022 |
Is SUFENTANIL in shortage in Canada?
A Canadian shortage report is on file for a product containing this molecule: Active — reported by STERIMAX INC, last seen 04 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Other Canadian products sharing ATC code N01AH03 SUFENTANIL. 2 of 5 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| SUFENTANIL CITRATE INJECTION USP | 50 MCG | SOLUTION | SANDOZ CANADA INCORPORATED | MARKETED | DIN 02244147 |
| SUFENTANIL CITRATE INJECTION USP | 50 MCG | SOLUTION | STERIMAX INC | MARKETED | DIN 02442213 |
| SUFENTA INJ 50MCG/ML | 50 MCG | LIQUID | JANSSEN PHARMACEUTICA, DIVISION OF JANSSEN-ORTHO INC. | CANCELLED POST MARKET | DIN 00619744 |
| SUFENTA INJ 50MCG/ML | 50 MCG | LIQUID | JANSSEN INC | CANCELLED POST MARKET | DIN 01951319 |
Who else supplies SUFENTANIL worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. SUFENTANIL appears in 686 registered pack listings across 6 markets, published on 4 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
This product is approved by Health Canada but not yet marketed in Canada, so there is no Canadian supply to draw on today. Nexara can tell you whether it has been launched, and can look at supply from other markets where a Canadian pack is not required or where importation is permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.